Lord, Abbett & Co. LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Lord, Abbett & Co. LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Oct 07, 2024	SELL	$23.9 - $35.38 $7,289 - $10,790	-305 Reduced 0.09%	332,597 $10.6 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $7,289 - $10,790	-305 Reduced 0.09%	332,597 $10.6 Million
Q1 2023 Oct 07, 2024	SELL	$22.82 - $35.32 $18 Million - $27.9 Million	-788,664 Reduced 70.32%	332,902 $8.12 Million
Q1 2023 May 12, 2023	SELL	$22.82 - $35.32 $18 Million - $27.9 Million	-788,664 Reduced 70.32%	332,902 $8.12 Million
Q4 2022 Oct 07, 2024	BUY	$25.35 - $31.96 $28.4 Million - $35.8 Million	1,121,566 New	1,121,566 $35.4 Million
Q4 2022 Feb 10, 2023	BUY	$25.35 - $31.96 $902,713 - $1.14 Million	35,610 Added 3.28%	1,121,566 $35.4 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $2.12 Million - $3.44 Million	82,992 Added 8.27%	1,085,956 $30.7 Million
Q2 2022 Aug 12, 2022	BUY	$20.62 - $37.15 $5.63 Million - $10.1 Million	273,114 Added 37.42%	1,002,964 $26.5 Million
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $16,097 - $24,235	685 Added 0.09%	729,850 $25.6 Million
Q4 2021 Feb 11, 2022	BUY	$29.21 - $44.64 $21.3 Million - $32.5 Million	729,165 New	729,165 $23.6 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.